NL-OMON31506已完成不适用
Co-culturing of primary chondrocytes and mesenchymal stem cells to optimize cartilage formation - INSTRUCT Technology
niversitair Medisch Centrum Utrecht0 个研究点目标入组 48 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Male and female patients over 18 years of age
- •-Patients with a ruptured ACL admitted to ACL reconstructive surgery
排除标准
- •-Patients over 40 years of age
- •-Patients with generalized cartilage degeneration
研究者
相似试验
未知
不适用
Cartilage repair with chondroprogenitor cells and bone marrow cellsOsteoarthritis of the kneeJPRN-UMIN000022540Shimane University Faculty of Medicine Dept. of Orthopaedic Surgery100
Unknown
1 期
Repair and Regeneration of Knee cartilageCTRI/2015/06/005841Sri Sathya Sai Institute of Higher Learning1
进行中（未招募）
1 期
Bone marrow transplantation from a donor to a patient who have incompatible blood cells. Before transplantation, patients will receive a less intensive treatment with a low-dose chemiotherapy. The day of transplantation, patients will be injected with a population of blood cells from the donor as well as a specific cell population, named mesenchymal stem cells.Hematological malignancies confirmed histologically and not rapidly progressing: - AML in Complete Remission- ALL in Complete Remission- CML unresponsive/intolerant to Imatinib but not in blast crisis- Other myeloproliferative disorders not in blast crisis and not with extensive myelofibrosis- MDS with < 5% blasts- Multiple myeloma not rapidly progressing- CLL- Non-Hodgkin’s lymphoma (aggressive NHL should have chemosensitive disease)- Hodgkin’s diseaseMedDRA version: 14.1Level: PTClassification code 10027703Term: Mismatched donor bone marrow transplantation therapySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2009-014980-38-BECHU de Liège120
已完成
1 期
use of chondrocytes cells for for bone growth plate injury in childreCTRI/2012/05/002638Christian Medical College Vellore5
招募中
2 期
Cotransplantation of mesenchymal stem cells with nonmyeloablative haploidentical peripheral blood stem cells without T cells deleted for high-risk acute leukemia: to reduce the severity of graft versus host disease and relapseHigh-risk acute leukemia patientsCancer - Leukaemia - Acute leukaemiaACTRN12608000129381Huisheng Ai40